Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

Subscribe Publication Updates

Publication Updates

11 Jun
AHFS Drug Information logo
AHFS Drug Information June 2018 update

This update contains 1 new monograph, 1 new MedWatch alert and 9 revised monographs.

New monograph: Ibalizumab-uiyk

Revised monographs: Chlorhexidine; Netupitant/Palonosetron, Deflazacort, Abaloparatide, Erythromycins General Statement, Extended-Spectrum Penicillins General Statement, Zidovudine, lamotrigine, lamivudine. 

11 Jun
Stockleys Drug Interactions_logo
Stockley’s Interactions Alerts June 2018 update

For June, 67 new Alerts have been added, and 64 existing Alerts have been updated.

11 Jun
Martindale logo
Martindale June 2018 update

This update contains 11 new monographs and 28 existing monographs have been updated. Preparations have been updated for 5 countries. 

New Monographs:

  • Bictegravir: is an HIV-integrase inhibitor used in the treatment of HIV infection. 
  • Cerliponase alfa: is a recombinant enzyme used to slow the loss of motor function and language skills in symptomatic patients with late-infantile neuronal ceroid lipofuscinosis type 2. 
  • Ertugliflozin: is a sodium-glucose co-transporter 2 inhibitor that is used for the treatment of type 2 diabetes mellitus. 
  • Gusekumab: is an antibody that targets interleukin-23 and is used for the treatment of plaque psoriasis. 
  • Letermovir: is a CMV DNA terminase complex inhibitor that is used for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant. 
  • Macimorelin: is a growth hormone stimulant used orally for the diagnosis of adult growth hormone deficiency. 
  • Migalastat: is a stabiliser of the alpha galactosidase A enzyme that is used orally in the treatment of Fabry disease. 
  • Naldemedine: is a peripherally-acting opioid antagonist used for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain. 
  • Ozenoxacin: is a quinolone antibacterial applied topically in the treatment of impetigo. 
  • Semaglutide: is a glucagon-like peptide 1 receptor agonist used in the treatment of type 2 diabetes mellitus. 
  • Voretigene neparvovec: is a gene therapy product used for treating biallelic RPE65 mutation-associated retinal dystrophy. 

Notable revisions:

  • Asfotase alfa: also licensed for paediatric-onset hypophosphatasia. Adverse effects and precautions has been updated. 
  • Canagliflozin: abstract on risk of amputation added. 
  • Ceftriaxone Sodium: uses and administration has been updated. 
  • Ceritinib: uses extended to include first-line treatment of metastatic non-small cell lung cancer. 
  • Desmopressin:  new abstract on administration added. Uses and administration has been updated. 
  • Eculizumab: also licensed for use in myasthenia gravis. 
  • Empagliflozin: also licensed to reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus. 
  • Interferon Alfa: also licensed for the treatment of hepatitis B in children. Adverse effects have been updated.  
  • Metformin: diabetes mellitus abstract has been updated with information on use in the prevention of type 2 diabetes mellitus. 
  • Methylthioninium Chloride: new record on incompatibility added and administration in children abstract has been updated. 
  • Ocrelizumab: also licensed for the treatment of relapsing and primary progressive multiple sclerosis. 
  • Ulipristal acetate: use for treating uterine fibroids restricted following reports of serious liver injury. 

Updated names, synonyms and codes; official standards; official preparation: Ph Eur 9.3 and USP40/USNF35 Suppl 1 and 2. 

Proprietary Preparations and Manufacturers updated for the following countries and regions:  India, Philippines, UK†, USA†, Venezuela. († Countries updated on an ongoing basis) 

11 Jun
Clarke's Analysis of Drugs and Poisons logo
Clarke’s June 2018 update

Update contains 37 new NPS monographs, 3 full revisions and 3 selective revisions, as well as minor updates. 

This update contains: 

  • 5 new full NPS monographs
  • 3 fully revised NPS monographs
  • 32 new foundation NPS monographs
  • 42 Spectra, which have been expanded to include LCMS/MS spectra
  • Updated prelims
  • Updated indices
11 Jun
British National Formulary for Children logo
BNFC June 2018 update

This update contains 5 significant changes, 4 new preparations and 3 dose changes. 

Significant Changes: 

 

Asthma, chronic: updated guidance on management.

Immunoglobulins: updated guidance for Varicella-zoster immunoglobulin.

Quinine: clarification of parenteral dose for the treatment of malaria [dose reduction necessary if parenteral treatment is required for more than 48 hours].

Vaccines: updated guidance for Hepatitis A Vaccine.Vaccines for travel: updated guidance on Hepatitis A. 

 

Dose Changes: Co-codamol [doses for children aged 12 to 15 years].

Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide [age-range extension].

Raltegravir [dose for oral suspension—new dose for neonates and update to dose for child with body-weight 3kg; update to directions for administration for oral suspension].  

 

New Preparations: 

 

Hemlibra® [emicizumab], RoActemra® preparations [tocilizumab], Truvada®[emtricitabine with tenofovir disoproxil], Yervoy® [ipilimumab].

 

For further details on changes in the BNFC click on changes

11 Jun
British National Formulary logo
BNF June 2018 update

This update contains 11 significant changes, 5 new preparations and 6 dose changes. 

Significant Changes:

Asthma, chronic: updated guidance on management.
Brodalumab for treating moderate to severe plaque psoriasis [NICE guidance]
Cabozantinib for treating medullary thyroid cancer [NICE guidance].
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen [NICE guidance].
Immunoglobulins: updated guidance for Varicella-zoster immunoglobulin.
Obeticholic acid (Ocaliva®): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring [MHRA/CHM advice].
Obinutuzumab for untreated advanced follicular lymphoma [NICE guidance].
Quinine: clarification of parenteral dose for the treatment of malaria [dose reduction necessary if parenteral treatment is required for more than 48 hours].
Regorafenib for previously treated advanced hepatocellular carcinoma [NICE guidance].
Vaccines: updated guidance for Hepatitis A Vaccine.
Vaccines for travel: updated guidance on Hepatitis A.

Dose changes:

Bosutinib [update to dose in renal impairment].
Candesartan cilexetil [clarification of maximum daily dose in heart failure].
Dexibuprofen.
Haloperidol [clarification of continuous subcutaneous dose for nausea and vomiting in palliative care].
Nivolumab [doses for monotherapy].
Temocillin.

New Preparations:

AirFluSal® preparations [fluticasone with salmeterol], Fasenra® [benralizumab], Hemlibra® preparations [tocilizumab], Rydapt® [midostaurin].

For further details on changes in the BNF click on changes.

View more